Abstract library

189 results for "recurrence".
#2792 Post-Transplant Recurrence of Neuroendocrine Tumors
Introduction: Recurrence after liver transplantation (LT) for metastases from NET is observed in 30-50% of cases at 5 years after LT but management is individualized
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Surgical treatment and Ablative Therapies
Presenting Author: MD Michela Monteleone
#2961 Our Experience Using a New Scoring System to Detect Disease Recurrence after Curative Surgical Resection of Well-Differentiated Pancreatic Neuroendocrine Tumors
Introduction: For patients with nonfunctioning pNET  ≥20 mm in size without distant metastasis, complete surgical resection is recommended as the primary curative strategy. Effective follow‐up programs are designed to detect recurrence at an early stage, given that treatment of limited disease has the most favorable outcome. However, data on post‐curative surgical recurrence remains limited, making it challenging to determine the best follow‐up strategy and to detect the best treatment options as an adjuvant therapy for selected patients.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Surgical treatment and Ablative Therapies
Presenting Author: MD Laura Mastrangelo
#2926 O-Positive Blood Group Is Associated with Prolonged Recurrence-Free Survival Following Pancreatic Neuroendocrine Tumor (PanNET) Curative-Intent Surgical Resection
Introduction: The ABO blood group may influence the development and progression of cancer. In particular, the prognosis of pancreatic adenocarcinoma is better in patients with blood group O. This has not been extensively explored in PanNET.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Dr Louis de Mestier
#2856 Pattern of Disease Recurrence and Treatment after Radical Surgery for Nonfunctioning Pancreatic Neuroendocrine Tumors (NF-PanNET)
Introduction: The risk of recurrence after radical surgery performed for pancreatic neuroendocrine tumors (PanNET) is reported between 10 and 30%. Nowadays, no adjuvant therapy is recommended for these patients and specific treatments are offered only when recurrence occurs. Nevertheless, among the available systemic and locoregional treatments, there are no specific recommendations on which the best option could be for treating recurrent disease.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Surgical treatment and Ablative Therapies
Presenting Author: MD Valentina Andreasi
#2784 Predictive Factors of Tumor Recurrence after Radical Surgery for Gastro-Entero-Pancreatic Neuroendocrine Neoplasms (GEP-NENs): Identification of High-Risk Subgroups
Introduction: There is no proven role for adjuvant medical therapy after curative surgery (R0) for GEP-NENs.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Dr Roberta Elisa Rossi
#2934 Vasostatin-1 Predicts Recurrence in Patients Submitted to Surgery for Nonfunctioning Pancreatic Neuroendocrine Tumors (NF-PanNET)
Introduction: An association between preoperative Vasostatin-1 (VS-1) plasma level and pathological features of aggressiveness was previously reported in patients with surgically resected nonfunctioning (NF) PanNET.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: MD Valentina Andreasi
#3010 International Validation of a Nomogram to Predict Recurrence after Resection of Grade 1 and 2 Pancreatic Neuroendocrine Tumors
Introduction: A prediction model to predict recurrence within 5 years after surgery for nonfunctional pancreatic neuroendocrine tumors (PanNets) was recently published. This model includes WHO tumor grade, lymph node status and perineural invasion as predictors.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Surgical treatment and Ablative Therapies
Presenting Author: drs Charlotte Heidsma
#2850 A Clinical Controlled Observation of Chinese Herbal Decoction (SMLJ01) for Type 1 Gastric Neuroendocrine Neoplasms
Introduction: Type 1 gastric neuroendocrine neoplasms (g-NENs) usually have good prognosis, however, most patients(pts) experience the recurrence after endoscopic resection.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - others, not specified
Presenting Author: Prof. Huang-Ying Tan
Authors: Chen Y Y, Han D, Zhu J Q, Chen J, ...
#2886 Risk Factors for Short Recurrence-Free Survivals after Resection of PanNET Liver Metastasis: Single Institutional Analysis
Introduction: Although the treatment of PanNEN has improved survivals with development of pharmacotherapy recently, surgery is the first choice if curative resection is expected to be achieved. However, most of the patients undergo recurrence after resection of the liver metastasis even after curative resection. Therefore, it is important to identify who gains longer RFS by resection.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Surgical treatment and Ablative Therapies
Presenting Author: M.D., Ph.D. Toshihiko Masui
Authors: Masui T, Anazawa T, Nagai K, Sato A, ...
#2963 Intrinsic Gene Programs in Metastasis-like Primary Subtype Is Associated with Early Metastatic Evolution in Pancreatic Neuroendocrine Tumours
Introduction: Three molecular subtypes of pancreatic neuroendocrine tumours (PanNETs) have been described: insulinoma-like, intermediate and metastasis-like primary (MLP). The Latter is a non-functional tumours with highly metastatic potential. A mouse model of PanNET showed that MLP subtype has two different pathways of progression including stem/progenitor and epithelial-to-mesenchymal transition. However, the evolution of metastasis in patients requires further studies.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Basic Science - Genetics, epigenetics, miRNAs, Omics
Presenting Author: Dr Anguraj Sadanandam